$-0.31 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED)

February 26, 2018 - By Marguerite Chambers

 $ 0.31 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED)
Investors sentiment increased to 0.71 in Q3 2017. Its up 0.12, from 0.59 in 2017Q2. It is positive, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported.
Proshare Advsr Ltd Company, a Maryland-based fund reported 21,195 shares. Geode Capital Mngmt Lc reported 0% stake. Primecap Management Ca holds 5.57 million shares. Zacks Mngmt invested in 0% or 23,997 shares. D E Shaw And stated it has 158,016 shares. Bridgeway Capital Mngmt Incorporated reported 88,900 shares or 0% of all its holdings. Connor Clark & Lunn Invest Mngmt accumulated 69,900 shares or 0% of the stock. First Eagle Investment Ltd Liability Corporation, a New York-based fund reported 219,420 shares. Goldman Sachs Grp Inc Incorporated reported 27,453 shares stake. Moreover, Cannell Peter B & Incorporated has 0.05% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Morgan Stanley reported 36,055 shares. 3,600 were accumulated by Glenmede Na. 350,000 were accumulated by Iguana Health Mngmt Ltd Liability Com. Ameriprise Fincl holds 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 911,184 shares. Northern reported 65,799 shares.

Since October 10, 2017, it had 0 insider purchases, and 5 sales for $27,111 activity. Hager Alicia J. had sold 1,248 shares worth $5,295 on Tuesday, October 10. Gurney Austin sold 1,248 shares worth $5,295. Shares for $5,295 were sold by Patel Sunil. HASTINGS PAUL J sold 1,398 shares worth $5,931.

Analysts expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report $-0.31 EPS on March, 14.They anticipate $0.39 EPS change or 55.71 % from last quarter’s $-0.7 EPS. After having $-0.28 EPS previously, OncoMed Pharmaceuticals, Inc.’s analysts see 10.71 % EPS growth. It closed at $2.16 lastly. It is down 70.06% since February 26, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Ratings Coverage

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Mizuho on Wednesday, January 6. The firm earned “Buy” rating on Thursday, August 24 by Jefferies. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Buy” rating given on Monday, April 18 by Cantor Fitzgerald. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, September 22 report. On Tuesday, September 26 the stock rating was maintained by Jefferies with “Buy”. On Tuesday, April 11 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. The firm earned “Outperform” rating on Tuesday, April 12 by BMO Capital Markets. Wells Fargo initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Friday, December 4 with “Outperform” rating. Jefferies initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Wednesday, September 9 with “Buy” rating.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $81.77 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Globenewswire.com which released: “OncoMed Announces Chairman, President and Chief Executive Officer Paul J …” on January 04, 2018, also Seekingalpha.com with their article: “Is OncoMed A Contrarian Buy?” published on May 25, 2017, Globenewswire.com published: “OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August …” on July 26, 2017. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Globenewswire.com and their article: “OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence” published on September 19, 2017 as well as Seekingalpha.com‘s news article titled: “OncoMed Pharmaceuticals’ (OMED) CEO Paul Hastings on Q2 2017 Results …” with publication date: August 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.